2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T598,Dapsone (4,4'-Diamino diphenyl sulfone) has been utilized in managing a wide variety of mucocutaneous conditions, usually as a systemic product. Topical dapsone is commercially available as 5% and 7.5% gel and is FDA-approved for acne vulgaris. These topical formulations have shown less systemic absorption and fewer adverse events. Considering this, topical dapsone might benefit localized disease, immunosuppressed individuals, and those who avoid exposure to systemic therapies. Following PRISMA guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, and Scopus databases for published papers up to April 2025. Then, eligible studies are included, and we summarize the findings of different clinical studies concerning the use, efficacy, and side effects of topical dapsone in various mucocutaneous conditions, excluding acne vulgaris. Finally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others. In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.31:T6da,ABSTRACTBackgroundDapsone (4,4′‐Diamino diphenyl sulfone) has been utilized in managing a wide variety of mucocutaneous conditions, usually as a systemic product. Topical dapsone is commercially available as 5% and 7.5% gel and is FDA‐approved for acne vulgaris. These topical formulations have shown less systemic absorption and fewer adverse events. Considering this, topical dapsone might benefit localized disease, immunosuppressed individuals, and those who avoid exposure to systemic therapies.MethodsFollowing PRISMA guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, and Scopus databases for published papers up to April 2025. Then, eligible studies are included, and we summarize the findings of different clinical studies concerning the use, efficacy, and side effects of topical dapsone in various mucocutaneous conditions, excluding acne vulgaris.ResultsFinally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others.ConclusionIn conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Topical Sulfone: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Topical Sulfone (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Topical%20Sulfone\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Topical Sulfone\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Topical%20Sulfone\"}]}}"}}]],["$","$L2f",null,{"title":"Topical Sulfone: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Topical Sulfone — concise summaries and practical next steps.","papers":[{"doi":"10.1111/jocd.70494","pmid":"41051026","title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies","journal_title":"Journal of Cosmetic Dermatology","journal_issn":"1473-2130","published_at":"2025-10-06T00:00:00.000Z","url":"https://doi.org/10.1111/jocd.70494","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-12","doi":"10.1111/jocd.70494","days":"7","issn":"1473-2130","rank":"9","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jocd.70494","title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies.","journal":"Journal of cosmetic dermatology","methods":"","results":"Finally, 56 articles were selected based on the eligibility criteria. We summarized and categorized them into two general entities, including applications of the topical dapsone and side effects of the topical dapsone. The first entity has six subheadings consisting of acne vulgaris and acneiform eruptions, Rosacea, neutrophilic dermatosis, vesiculobullous diseases, vasculitis, and others.","abstract":"$30","keywords":["dapsone","dermatology","skin","sulfones","topical"],"pubmed_id":"41051026","conclusions":"In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.","publication_date":"2025-10-06T00:00:00"},"crossref":{"DOI":"10.1111/jocd.70494","URL":"https://doi.org/10.1111/jocd.70494","ISSN":["1473-2130","1473-2165"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.70494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"10","score":1,"title":["Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies"],"author":[{"given":"Bahareh","family":"Abtahi‐Naeini","sequence":"first","affiliation":[{"name":"Pediatric Dermatology Division, Department of Pediatrics Imam Hossein Children's Hospital, Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Skin Diseases and Leishmaniasis Research Center Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Hossein","family":"Sattari","sequence":"additional","affiliation":[{"name":"Clinical Research Development Center, Najafabad Branch Islamic Azad University Najafabad Iran"},{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Kimia","family":"Afshar","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Fereshte","family":"Rastegarnasab","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"}]},{"given":"Mahsa","family":"Pourmahdi‐Boroujeni","sequence":"additional","affiliation":[{"name":"Student Research Committee Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Isfahan Eye Research Center Isfahan University of Medical Sciences Isfahan Iran"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"24","archive":["Portico"],"created":{"date-time":"2025-10-06T23:34:06Z","timestamp":1759793646000,"date-parts":[[2025,10,6]]},"indexed":{"date-time":"2025-10-16T08:40:44Z","timestamp":1760604044979,"date-parts":[[2025,10,16]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000,"date-parts":[[2025,10,6]]},"delay-in-days":5,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70494"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-09"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-26"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-06"}],"deposited":{"date-time":"2025-10-16T08:15:38Z","timestamp":1760602538000,"date-parts":[[2025,10,16]]},"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.21037/apm-21-3935","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/17425255.2019.1600670","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-013-1409-7","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ijd.14761","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/15569527.2021.2024565","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/1203475416651053","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ipd.12615","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_9_1","year":"2012","issue":"4","author":"Handler M. Z.","volume":"6","first-page":"132","unstructured":null,"article-title":"Letter to the Editor: Application of Dapsone 5% Gel in a Patient With Dermatitis Herpetiformis","journal-title":"Journal of Dermatology Case Reports","doi-asserted-by":null},{"DOI":"10.1177/1203475418795818","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_11_1","year":"2011","issue":"9","author":"Handler M. Z.","volume":"10","first-page":"1059","unstructured":null,"article-title":"Treatment of Peristomal Pyoderma Gangrenosum With Topical Crushed Dapsone","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1177/1203475418782140","key":"e_1_2_11_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.13471","key":"e_1_2_11_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14953","key":"e_1_2_11_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2011.10.011","key":"e_1_2_11_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.07.004","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/ijt.ijt_39_22","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.4103/ds.DS-D-24-00037","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_19_1","year":"2013","issue":"4","author":"Frieling G. W.","volume":"12","first-page":"481","unstructured":null,"article-title":"Novel Use of Topical Dapsone 5% Gel for Erythema Elevatum Diutinum: Safer and Effective","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_20_1","year":"2017","issue":"6","author":"Pate D. A.","volume":"99","first-page":"426","unstructured":null,"article-title":"Leukocytoclastic Vasculitis Resolution With Topical Dapsone","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_21_1","year":"2016","issue":"4","author":"Aflatoonian M.","volume":"26","first-page":"353","unstructured":null,"article-title":"The Efficacy of Combined Topical Niosomal Dapsone Gel and Intralesional Injection of Meglumine Antimoniate in Comparison With Intralesional Meglumine Antimoniate and Cryotherapy in the Treatment of Cutaneous Leishmaniasis","journal-title":"Journal of Pakistan Association of Dermatologists","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_22_1","year":"2015","issue":"6","author":"Faghihi G.","volume":"14","first-page":"602","unstructured":null,"article-title":"Dapsone Gel in the Treatment of Papulopustular Rosacea: A Double‐Blind Randomized Clinical Trial","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1080/15569527.2024.2424932","key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.13742","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_25_1","year":"2024","issue":"1","author":"Gökşin Ş.","volume":"14","first-page":"1","unstructured":null,"article-title":"Efficacy of Topical Dapsone 5% Gel for the Treatment of Erythematotelangiectatic Rosacea: New Treatment Option With Old Drug","journal-title":"Dermatology Practical & Conceptual","doi-asserted-by":null},{"DOI":"10.1159/000431171","key":"e_1_2_11_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.5070/D3208023535","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_28_1","year":"2015","issue":"7","author":"Kassardjian M.","volume":"8","first-page":"48","unstructured":null,"article-title":"Management of Periocular Granuloma Annulare Using Topical Dapsone","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_29_1","year":"2015","issue":"5","author":"Watton C.","volume":"372","first-page":"492","unstructured":null,"article-title":"Methemoglobinemia as a Complication of Topical Dapsone","journal-title":"New England Journal of Medicine","doi-asserted-by":null},{"DOI":"10.1542/peds.2015-3186","key":"e_1_2_11_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.14080","key":"e_1_2_11_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_11_32_1","year":"2022","issue":"9","author":"Cantrell C.","volume":"14","first-page":null,"unstructured":null,"article-title":"Refractory Methemoglobinemia Secondary to Topical Dapsone With Subsequent Autoimmune Hemolytic Anemia","journal-title":"Cureus Journal of Medical Science","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_11_33_1","year":"2015","issue":"1","author":"Del Rosso J. Q.","volume":"8","first-page":"31","unstructured":null,"article-title":"Comparative Efficacy and Tolerability of Dapsone 5% Gel in Adult Versus Adolescent Females With Acne Vulgaris","journal-title":"Journal of Clinical and Aesthetic Dermatology","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2006.10.005","key":"e_1_2_11_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jocd.70494"],"article-number":"e70494","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,10]]},"reference-count":33,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,6]]},"references-count":33,"short-container-title":["J of Cosmetic Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jocd.70494","is_oa":true,"title":"Efficacy and Safety of Topical Dapsone in Dermatology: A Scoping Review of Clinical Studies","updated":"2025-10-11T00:07:04+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://doi.org/10.1111/jocd.70494","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1111/jocd.70494"}}},"created_at":"2025-10-16T07:50:39.785Z","updated_at":"2025-10-18T07:47:19.581Z","tags":[{"paper_doi":"10.1111/jocd.70494","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Neutrophilic Dermatoses","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Rosacea","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Vasculitis","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"condition","value":"Vesiculobullous Diseases","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"generic","value":"dapsone","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"modality","value":"Topical Sulfone","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"sample_size","value":"n=56","value_numeric":56},{"paper_doi":"10.1111/jocd.70494","tag_type":"study_design","value":"Scoping Review","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"Heterogeneous conditions and designs make the study type classification and generalizability uncertain.","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"Only abstract-level details are available; no pooled or numeric outcomes were reported here.","value_numeric":null},{"paper_doi":"10.1111/jocd.70494","tag_type":"warning","value":"The abstract is inconsistent about excluding versus including acne vulgaris.","value_numeric":null}],"summaries":{"what_studied":"A PRISMA-guided scoping review searched PubMed, Web of Science, and Scopus through April 2025 and included 56 clinical articles on topical dapsone (5% or 7.5% gel) for mucocutaneous conditions, summarizing efficacy and side effects.","limitations":"The evidence is a scoping review across diverse conditions without quantified outcomes. The abstract conflicts on whether acne vulgaris was excluded or included.","practice_takeaway":"Topical dapsone (5% or 7.5% gel) may be an option for localized, chronic mucocutaneous eruptions when avoiding systemic therapy, but the support is heterogeneous and not quantified here."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Topical Sulfone"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Topical Sulfone"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Topical Sulfone"}}}]]

Papers